DDInter1066 DDInter1658
Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Lidocaine {u} (Compound) resembles {v} (Compound) Ropivacaine
Lidocaine {u} (Compound) resembles {v} (Compound) Chloroprocaine
Lidocaine {u} (Compound) binds {v} (Gene) CYP2C18
Lidocaine {u} (Compound) palliates {v} (Disease) coronary artery disease
Lidocaine {u} (Compound) is included by {v} (Pharmacologic Class) Local Anesthesia
Lidocaine {u} (Compound) downregulates {v} (Gene) PPP2R5E
Lidocaine {u} (Compound) causes {v} (Side Effect) Nausea
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Butalbital
Lidocaine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ixekizumab
Lidocaine (Compound) resembles Ropivacaine (Compound)
Lidocaine (Compound) resembles Chloroprocaine (Compound)
Lidocaine (Compound) binds CYP2C18 (Gene)
Lidocaine (Compound) palliates coronary artery disease (Disease)
Lidocaine (Compound) is included by Local Anesthesia (Pharmacologic Class)
Lidocaine (Compound) downregulates PPP2R5E (Gene)
Lidocaine (Compound) causes Nausea (Side Effect)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Butalbital
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab